C3 and paroxysmal nocturnal hemoglobinuria: Similarly, in clinical trials of patients with PNH, pegcetacoplan treatment induced a sustained increase in C3 concentrations [71], which could potentially result from a reduced C3 consumption due to the inhibition of complement activation by pegcetacoplan, or from an increased C3 half-life.